Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
复制标题
DOI：
10.1186/1471-2407-11-292
复制
发表时间：
2011-07-12
期刊：
影响因子：
3.8
通讯作者：
Shu XO
中科院分区：
文献类型：
--
作者：
Su Y;Zheng Y;Zheng W;Gu K;Chen Z;Li G;Cai Q;Lu W;Shu XO
乳腺癌的分子分类是一个重要的预后因素。乳腺癌分子亚型的分布及其预后价值在亚洲人中尚未得到很好的证明。通过免疫组化检测，对一项基于人群的队列研究中招募的2,791例乳腺癌患者进行了乳腺癌分子亚型的评估。通过集中病理学审查确认了临床病理学特征数据。平均随访53.4个月。根据乳腺癌的分子亚型评估了总体和无病生存率。管腔A、管腔B、人表皮生长因子受体2（HER 2）和三阴性亚型的患病率分别为48.6%、16.7%、13.7%和12.9%。与三阴性或HER 2亚型相比，管腔A亚型更容易在老年女性中被诊断（P = 0.03），并且与有利的临床病理因素（较小的肿瘤大小，较低的组织学分级和较早的TNM分期）具有更强的相关性。三阴性乳腺癌患者的乳腺癌家族史频率高于其他亚型（P = 0.048）。管腔型A、管腔型B、HER 2和三阴性亚型的5年总体/无病生存率百分比分别为92.9%/88.6%、88.6%/85.1%、83.2%/79.1%和80.7%/76.0%。在多变量分析中观察到类似的模式。免疫治疗与管腔A型乳腺癌的总体和无病生存期改善相关，但与HER 2亚型乳腺癌的无病生存期降低相关（HR = 2.21，95% CI，1.09-4.48）。在这些中国女性中，与管腔A亚型相比，三阴性和HER 2亚型与较差的结局相关。与西方人群相比，该中国人群中的HER 2亚型更普遍，这表明标准化HER 2检测和抗HER 2治疗对中国高比例乳腺癌患者的潜在获益具有重要意义。
Molecular classification of breast cancer is an important prognostic factor. The distribution of molecular subtypes of breast cancer and their prognostic value has not been well documented in Asians. A total of 2,791 breast cancer patients recruited for a population-based cohort study were evaluated for molecular subtypes of breast cancer by immunohistochemical assays. Data on clinicopathological characteristics were confirmed by centralized pathology review. The average follow-up of the patients was 53.4 months. Overall and disease-free survival by molecular subtypes of breast cancer were evaluated. The prevalence of the luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative subtypes were 48.6%, 16.7%, 13.7%, and 12.9%, respectively. The luminal A subtype was more likely to be diagnosed in older women (P = 0.03) and had a stronger correlation with favorable clinicopathological factors (smaller tumor size, lower histologic grade, and earlier TNM stage) than the triple-negative or HER2 subtypes. Women with triple-negative breast cancer had a higher frequency of family history of breast cancer than women with other subtypes (P = 0.048). The 5-year overall/disease-free survival percentages for the luminal A, luminal B, HER2, and triple-negative subtypes were 92.9%/88.6%, 88.6%/85.1%, 83.2%/79.1%, and 80.7%/76.0%, respectively. A similar pattern was observed in multivariate analyses. Immunotherapy was associated with improved overall and disease-free survival for luminal A breast cancer, but reduced disease-free survival (HR = 2.21, 95% CI, 1.09-4.48) for the HER2 subtype of breast cancer. The triple-negative and HER2 subtypes were associated with poorer outcomes compared with the luminal A subtype among these Chinese women. The HER2 subtype was more prevalent in this Chinese population compared with Western populations, suggesting the importance of standardized HER2 detection and anti-HER2 therapy to potentially benefit a high proportion of breast cancer patients in China.
登录
查看更多内容
影响因子：
120.7
作者：
Shu, Xiao Ou;Zheng, Ying;Cai, Hui;Gu, Kai;Chen, Zhi;Zheng, Wei;Lu, Wei
通讯作者：
Lu, Wei
影响因子：
3.8
作者：
Telli, Melinda L.;Chang, Ellen T.;Kurian, Allison W.;Keegan, Theresa H. M.;McClure, Laura A.;Lichtensztajn, Daphne;Ford, James M.;Gomez, Scarlett L.
通讯作者：
Gomez, Scarlett L.
影响因子：
3.8
作者：
Su, Yinghao;Shrubsole, Martha J.;Zheng, Wei
通讯作者：
Zheng, Wei
影响因子：
2.1
作者：
Parise, Carol A.;Bauer, Katrina R.;Caggiano, Vincent
通讯作者：
Caggiano, Vincent
影响因子：
2
作者：
Diaz, Leslie K;Sahin, Aysegul;Sneige, Nour
通讯作者：
Sneige, Nour